Diagnostic Performance of a New Rapid Lateral Flow Immunoassay in Patients Suspected of Heparin-Induced Thrombocytopenia and Its Clinical Consequences

Berroëta, Clarisse; Crespin, Malvina; Bouabdallah, K.; Pargade, S; Huchet, François-Xavier; Bourel, Patrick; Philip, Ivan; Lebuisson, Agathe

doi:10.1055/s-0035-1564840

Cited by 12 publications

(8 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…66,67 Stago Diagnostics also offers a process for HIT testing, but this is a manual test using lateral flow technology (i.e., no hemostasis instrumentation is involved). [66][67][68] It is expected that HIT testing will become more widely available on mainstream hemostasis instrumentation in the future.…”

Section: Assessing Factor Levels In the New Era Of Extended Life Factmentioning

confidence: 99%

Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Favaloro

Lippi

2019

Semin Thromb Hemost

View full text Add to dashboard Cite

The authors provide a narrative review of mainstream hemostasis analyzers. The review is presented in two parts. In the first part, the authors give voice to several internationally representative manufacturers of mainstream hemostasis analyzers. They ask these manufacturers to (1) answer a series of survey questions that may otherwise reflect common questions asked by users or potential users of their equipment, (2) provide a bullet list of their main focus areas, and (3) provide other information in regard to their instrumentation. The authors then offer their own personal perspective of the benefits of various aspects of such equipment, as well as a sampling of some hemostasis tests as currently available, or potentially in progress. It is hoped that this snapshot of mainstream hemostasis diagnostics and coagulation testing drives positive future changes that will ultimately provide the best outcomes for laboratories performing hemostasis assays and the patients they help diagnose and manage.

show abstract

Section: Assessing Factor Levels In the New Era Of Extended Life Factmentioning

confidence: 99%

Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Favaloro

Lippi

2019

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

“…There are two broad classes of HIT tests: immunological assays that detect heparin‐PF4 antibodies (Box 3), and functional assays that measure heparin‐dependent platelet activation and aggregation by these antibodies (Box 4). However, all HIT tests suffer several limitations related to sensitivity and specificity, or to complexity and accessibility …”

Section: Diagnosismentioning

confidence: 99%

Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New ZealandHITWriting Group

Joseph

Rabbolini

Enjeti

et al. 2019

Medical Journal of Australia

View full text Add to dashboard Cite

H eparin-induced thrombocytopenia (HIT) is a prothrombotic adverse reaction to heparin characterised by platelet-activating antibodies (almost exclusively IgG) that recognise and bind to platelet factor 4 (PF4)-heparin complexes. While antibody formation is common (up to 50% in the setting of cardiac surgery), only a small proportion of patients (0.2-3.0%) develop HIT (ie, thrombocytopenia and/or thrombosis). 1 Thrombosis can be arterial, venous or microvascular. Incidence of HIT varies depending on clinical setting (higher in surgical than medical, rarely in paediatric or obstetric), type of heparin (unfractionated heparin has higher rates than low molecular weight heparin), and dose (therapeutic v prophylactic). 2 PF4 tetramers (cationic) and heparin (anionic) associate by charge and hence certain molar concentrations (1:1 molar ratio) facilitate charge neutralisation, conformational change in PF4-exposing pathogenic epitopes, antibody binding and PF4-heparin-IgG complex formation. 3 PF4 can also bind to other polyanions, including glycosaminoglycans and chondroitin sulfate, and such interactions may play a role in the increasingly reported entity known as spontaneous HIT syndrome; that is, patients with clinical and laboratory features of HIT without exposure to heparin.Thrombocytopenia and thrombosis in HIT result from the binding of PF4-heparin-IgG complex to FcγRIIa receptors on the platelet surface. Subsequent cross-linking of the receptors leads to intense platelet activation, release of platelet granule content and procoagulant microparticles, thrombin generation, and activation of endothelial cells, neutrophils and monocytes. 4HIT is a clinicopathological entity and therefore requires integration of clinical and laboratory results. Accurate diagnosis is important and consultation with an appropriate specialist is recommended as delay in diagnosis and appropriate anticoagulant treatment is associated with an initial 6% daily risk of thromboembolism as well as amputation and death. 5 MethodsAustralian and New Zealand experts in the field of thrombosis and haemostasis who regularly diagnose and treat HIT syndrome were invited to a consensus statement development panel. This group, the Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) HIT Writing Group, represents THANZ members and received formal endorsement from the THANZ President. A comprehensive literature review, using common online databases, was undertaken for each subsection by at least two authors. Major computerised databases such as Cochrane, MEDLINE and EMBASE were utilised. These searches were further supplemented with review of reference lists and professional society information available from internet sources. A draft for each subsection, collated by its two authors after extensive literature review, was submitted to the lead author (JJ). Following this comprehensive review of the literature, a face-to-face meeting was held over 2 days to discuss specific questions and finalise a draft of the consensus statement. Durin...

show abstract

“…The incidence of PaGIA reported in India ranges from 1.4 to 23% [11][12][13][14] and the data from different studies from India are compared in Table 3. Kapadia et al [11] had reported PaGIA positivity 1.4%.…”

Section: Discussionmentioning

confidence: 99%

“…In the present study, nine patients were from ICU and 8 were from medical ward. Among There are a few studies available worldwide on STic Ò Expert HIT [14][15][16] and none from India. The comparison of worldwide studies on STic Ò Expert HIT is tabulated (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Kumar

Uppal

Ahluwalia

et al. 2018

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Heparin-induced thrombocytopenia (HIT) is an adverse drug reaction caused by heparin. HIT occurs due to IgG antibodies directed against heparin-bound platelet factor 4 (PF4). The aim of this study was to evaluate the STic Ò Expert HIT for detection of anti-PF4/heparin antibodies in comparison with ID-PaGIA TM kit. The results were further confirmed by Heparin-induced platelet aggregation test (HIPA). A total of 17 patients with a suspected diagnosis of HIT were enrolled. The 4 T scoring of each case was performed. Testing for HIT was carried out by ID-PaGIA TM , STic Ò Expert HIT, and HIPA. Testing by STic Ò Expert HIT test demonstrated positivity in three cases while testing by ID-PaGIA TM test kit revealed four positive cases. Two of these cases were confirmed as HIT by HIPA. The study suggests that STic Ò Expert HIT an equally effective test, in combination with the 4T scoring system for detecting/excluding the diagnosis of HIT. A large number of cases are needed for validation.

show abstract

Diagnostic Performance of a New Rapid Lateral Flow Immunoassay in Patients Suspected of Heparin-Induced Thrombocytopenia and Its Clinical Consequences

Cited by 12 publications

References 19 publications

Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Recent Advances in Mainstream Hemostasis Diagnostics and Coagulation Testing

Diagnosis and management of heparin‐induced thrombocytopenia: a consensus statement from the Thrombosis and Haemostasis Society of Australia and New ZealandHITWriting Group

Evaluation of STic Expert® HIT Kit and Its Comparison with ID-PaGIA™ Test in Suspected Heparin-Induced Thrombocytopenia

Contact Info

Product

Resources

About